Supplementary

Table S1 Proportion of patients who completed and were compliant with QLQ-C30 and QLQ-LC13 in TD-FOREKNOW trial

Time point	Camrelizumab plus chemotherapy cohort	Chemotherapy cohort
QLQ-C30		
Baseline	43 (100.0)[†]	45 (100.0)[†]
Week 4		
Completion	42 (97.7)	45 (100.0)
Compliance	42/42 (100.0)	45/45 (100.0)
Week 7		
Completion	42 (97.7)	45 (100.0)
Compliance	42/42 (100.0)	45/45 (100.0)
Week 12		
Completion	40 (93.0)	43 (95.6)
Compliance	40/40 (100.0)	43/43 (100.0)
Week 16		
Completion	39 (90.7)	42 (93.3)
Compliance	39/39 (100.0)	42/42 (100.0)
QLQ-LC13		
Baseline	43 (100.0)	45 (100.0)
Week 4		
Completion	42 (97.7)	45 (100.0)
Compliance	42/42 (100.0)	45/45 (100.0)
Week 7		
Completion	42 (97.7)	45 (100.0)
Compliance	42/42 (100.0)	45/45 (100.0)
Week 12		
Completion	40 (93.0)	43 (95.6)
Compliance	40/40 (100.0)	43/43 (100.0)
Week 16		
Completion	39 (90.7)	42 (93.3)
Compliance	39/39 (100.0)	42/42 (100.0)

[†], the patient-reported outcome analysis population included patients who completed ≥1 treatment dose and ≥1 PRO assessment. QLQ-C30, Quality of Life Questionnaire-Core 30; QLQ-LC13, Quality of Life Questionnaire-Lung Cancer Module 13.

https://dx.doi.org/10.21037/tlcr-2025-1-1425

Table S2 Mean changes from baseline in QLQ-C30 GHS/QoL score in TD-FOREKNOW trial

Time point	Camrelizumab plus chemotherapy cohort (n=43)	Chemotherapy cohort (n=45)
Baseline		
Completed questionnaire	43	45
Mean Score (SD)	74.2 (17.4)	74.4 (18.8)
Week 4		
Completed questionnaire	42	45
Mean Score (SD)	69.4 (16.3)	72.6 (17.9)
Change from baseline		
Included in analysis	43	45
Least-squares mean score (95% CI)	–4.97(–9.93, –0.02)	–1.84 (–6.62, 2.94)
Difference in LS mean (95% CI)	–3.13 (–10.00, 3.75); P=0.37	
Week 7		
Completed questionnaire	42	45
Mean Score (SD)	67.5 (18.4)	75.0 (17.1)
Change from baseline		
Included in analysis	43	45
Least-squares mean score (95% CI)	–6.89 (–13.16, –0.62)	0.64 (–5.47, 6.75)
Difference in LS mean (95% CI)	–7.53 (–15.15, 0.08); P=0.053	
Week 12		
Completed questionnaire	40	43
Mean Score (SD)	67.5 (19.1)	74.8(14.8)
Change from baseline		
Included in analysis	43	45
Least-squares mean score (95% CI)	–6.95 (–13.31, –0.59)	0.70 (–5.50, 6.90)
Difference in LS mean (95% CI)	–7.65 (–15.57, 0.03); P=0.051	
Week 16		
Completed questionnaire	39	42
Mean Score (SD)	72.4 (12.4)	70.8 (21.9)
Change from baseline		
Included in analysis	43	45
Least-squares mean score (95% CI)	–1.97 (–8.31, 4.36)	–3.46 (–9.61, 2.70)
Difference in LS mean (95% CI)	1.48 (–6.38, 9.35); P=0.71	

GHS/QoL, global health status/quality of life; LS, least squares; QLQ-C30, Quality of Life Questionnaire-Core 30; SD, standard deviation.

https://dx.doi.org/10.21037/tlcr-2025-1-1425

Table S3 Mean changes from baseline in cough, dyspnea and hemoptysis score in camrelizumab plus chemotherapy cohort

Time point	Cough		Dyspnea		Hemoptysis	
	pCR patients (n=14)	Non-pCR patients (n=26)	pCR patients (n=14)	Non-pCR patients (n=26)	pCR patients (n=14)	Non-pCR patients (n=26)
Baseline						
Mean Score (SD)	19.1 (21.5)	20.5 (19.0)	21.4 (24.8)	24.4 (24.1)	9.5 (15.6)	15.4 (19.4)
Week 4						
Mean Score (SD)	31.0 (24.3)	21.8 (24.8)	21.4 (16.6)	20.5 (19.0)	4.8 (12.1)	11.5 (16.2)
Change from baseline						
Least-squares mean score (95% CI)	11.2 (–1.9, 24.4)	1.6 (–8.0, 11.3)	–1.5 (–11.0, 8.1)	–3.1 (–10.1, 4.0)	–8.5 (–16.7, 0.2)	–1.8 (–7.9, 4.2)
Difference in LS mean (95% CI)	9.6 (–6.7, 25.9); P=0.240		1.6 (–10.3, 13.4); P=0.791		–6.6 (–16.9, 3.6); P=0.198	
Week 7						
Mean Score (SD)	9.5 (15.6)	18.0 (19.4)	9.5 (15.6)	18.0 (19.4)	0 (0)	7.7 (17.2)
Change from baseline						
Least-squares mean score (95% CI)	–10.2 (–19.6, –0.8)	–2.2 (–9.1, 4.7)	–13.4 (–23.0, –3.8)	–5.6 (–12.6, 1.5)	–13.9 (–21.5, –6.4)	–5.3 (–10.8, 0.2)
Difference in LS mean (95% CI)	–8.0 (–19.7, 3.7); P=0.175		–7.8 (–19.7, 4.1); P=0.192		–8.6 (–18.0, 0.8); P=0.071	
Week 12–14						
Mean Score (SD)	12.8 (21.7)	30.8 (20.9)	11.9 (21.1)	33.3 (26.7)	6.4 (13.4)	2.4 (8.9)
Change from baseline						
Least-squares mean score (95% CI)	–7.0 (–19.1, 5.0)	11.2 (2.2, 19.7)	–11.4 (–25.0, 2.3)	10.0(–0.1, 20.0)	–11.8 (–18.1, –5.6)	–6.5 (–11.0, –1.9)
Difference in LS mean (95% CI)	–18.2 (–33.0, –3.5); P=0.017		–21.3 (–38.3, –4.3); P=0.015		–5.4 (–13.2, 2.4); P=0.171	
Week 16–18						
Mean Score (SD)	33.3 (29.2)	32 (24.5)	32.5 (25.6)	27.8 (21.7)	14.3 (17.1)	24 (20.5)
Change from baseline						
Least-squares mean score (95% CI)	12.7 (–1.7, 27.1)	11.6 (0.8, 22.3)	9.2 (–5.2, 23.7)	8.2 (–2.6, 18.9)	–0.6 (–10.9, 9.7)	11.0 (3.4, 18.7)
Difference in LS mean (95% CI)	1.1 (–16.9, 19.1); P=0.902		1.1 (–17.0, 19.1); P=0.903		–11.7 (–24.6, 1.3); P=0.075	

CI, confidence interval; pCR, pathologic complete response; SD, standard deviation.

https://dx.doi.org/10.21037/tlcr-2025-1-1425

Table S4 Adverse events in camrelizumab plus chemotherapy cohort

Event	pCR patients (n=14)		Non-pCR patients(n=26)	
	Any grade	Grade ≥3	Any grade	Grade ≥3
Treatment-related adverse events				
Any	13 (92.8)	3 (21.4)	23 (88.5)	8 (30.8)
Alopecia	7 (50.0)	0	17 (65.4)	1 (3.8)
White blood cell count decreased	4 (28.6)	1 (7.1)	17 (65.4)	5 (19.2)
RCCEP	4 (28.6)	0	15 (57.7)	0
Neutrophil count decreased	4 (28.6)	2 (14.3)	8 (30.8)	1 (3.8)
Rash	2 (14.3)	0	6 (23.1)	0
Nausea	0	0	6 (23.1)	0
Vomiting	1 (7.1)	0	3 (11.5)	0
Hypothyroidism	1 (7.1)	0	2 (7.7)	0
Anemia	0	0	2 (7.7)	0
Diarrhea	0	0	1 (3.8)	0
Electrolyte disturbance	0	0	1 (3.8)	1 (3.8)
Hypertension	0	0	1 (3.8)	1 (3.8)
Myelodysplastic syndrome	1 (7.1)	1 (7.1)	0	0
Surgery-related adverse events				
Any	4 (28.6)	0	11 (42.3)	1 (3.8)
Pulmonary infection	1 (7.1)	0	1 (3.8)	0
Anemia	2 (14.3)	0	4 (15.4)	0
Pneumothorax	0	0	1 (3.8)	0
Intraoperative bleeding	1 (7.1)	0	5 (19.2)	0
Pleural effusion	0	0	1 (3.8)	0
Pulmonary embolism	0	0	1 (3.8)	0
Atrial fibrillation	0	0	1 (3.8)	0

Data are presented as n (%). pCR, pathologic complete response.

https://dx.doi.org/10.21037/tlcr-2025-1-1425